שווי כולל של החברה: Advanced Biomed Inc (ADVB)

Taiwanese oncology diagnostics developer Advanced Biomed Inc (ADVB) is mitigating geopolitical risks by relocating its operational processes and patents to the US. The business focuses on developing microfluidic systems for AI-powered automated blood analysis. This price chart reflects an Enterprise Value of 4.53, supporting the brand's ambitions to implement ultra-precise "liquid biopsy" methods for the earliest possible detection of pathologies.

Enterprise Value (EV) represents the total buyout price of a business, combining market capitalization and net debt. The charted value of the enterprise reflects the actual cost of acquiring the assets of Advanced Biomed Inc (ADVB) while accounting for liabilities. For liquid biopsy systems, this metric determines the capitalization efficiency of early cancer detection technologies. Analyzing the trend helps avoid overpaying at historical peaks. This indicator confirms the fundamental stability of the company.